Longitude Capital
  • ABOUT
  • TEAM
  • PORTFOLIO
  • NEWS
  • CONTACT
  • LP LOGIN
Select Page

Jazz Pharmaceuticals Announces That Patient Enrollment is Complete for the Phase 3 Study of JZP-110 Evaluating Excessive Sleepiness in Narcolepsy

by mparnell | Nov 28, 2016 | Portfolio News

Aimmune Therapeutics Completes Global Enrollment of Phase 3 PALISADE Trial of AR101 for the Treatment of Peanut Allergy

by mparnell | Nov 28, 2016 | Portfolio News

Aimmune Therapeutics Closes $145 Million Investment by Nestlé Health Science

by mparnell | Nov 28, 2016 | Portfolio News

Independent Review of Xtampza® ER Published in Peer-Reviewed Medical Journal

by mparnell | Nov 21, 2016 | Portfolio News

Aimmune Therapeutics Announces Third Quarter 2016 Financial Results and Provides Corporate Update

by mparnell | Nov 14, 2016 | Portfolio News

« Older Entries
Next Entries »

Media Contact

Maggie Jamison

mjamison@longitudecapital.com

650-854-5700

  • Facebook
  • Twitter
  • Google
  • RSS
footer-logo

LP Login

© 2023 Longitude Capital. All rights reserved.
  • Privacy Policy
  • Disclaimer